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Abstract 
Oesophageal adenocarcinoma (OAC) is an exemplar model of obesity-associated cancer. Response to 
neoadjuvant chemoradiotherapy (NA CRT) is a clinical challenge. We examined if visceral adipose tissue and 
obesity status alter radiosensitivity in OAC. 
The radioresistant (OE33R) and radioresponsive (OE33P) OAC isogenic model was cultured with adipose 
tissue conditioned media from three patient cohorts: non-cancer patients, surgery only OAC patients and NA 
CRT OAC patients. Cell survival was characterised by clonogenic assay, metabolomic profiling by nuclear 
magnetic resonance spectroscopy and adipokine receptor gene expression by qPCR. A retrospective in vivo 
study compared tumour response to NA CRT in normal weight (n=53) versus overweight/obese patients 
(n=148).  
Adipose conditioned media (ACM) from all patient cohorts significantly increased radiosensitivity in 
radioresistant OE33R cells. ACM from the NA CRT OAC cohort increased radiosensitivity in OE33P cells. 
Metabolomic profiling demonstrated separation of the non-cancer and surgery only OAC cohorts and between 
the non-cancer and NA CRT OAC cohorts. Gene expression profiling of OE33P versus OE33R cells 
demonstrated differential expression of the adiponectin receptor-1 (AR1), adiponectin receptor-2 (AR2), 
leptin receptor (LepR) and neuropilin receptor-1 (NRP1) genes. In vivo overweight/obese OAC patients 
achieved an enhanced tumour response following NA CRT compared to normal weight patients. This study 
demonstrates that visceral adipose tissue modulates the cellular response to radiation in OAC. 
Key words: oesophageal cancer, obesity, radiotherapy, visceral adipose tissue  
Introduction 
Oesophageal adenocarcinoma (OAC) is an 
aggressive disease with five-year survival rates of 
approximately 20%, and 40% for patients who are 
treated with curative intent (1). For locally advanced 
disease, neoadjuvant chemoradiation (NA CRT) is 
increasingly the standard of care (2-4). The CROSS 
trial demonstrated that NA CRT followed by surgery 
was associated with a greater than two-fold increase 
in median overall survival compared with surgery 
alone (2,3). A meta-analysis including CROSS and 
eleven randomised controlled trials (RCTs) of 
multimodal therapy compared with surgery alone 
concluded that NA CRT was associated with a 
significant improvement in overall survival (4). 
Tumour response to NA CRT predicts survival, but 
resistance to therapy remains a significant clinical 
problem with only 14-45% of patients achieving a 
complete pathological response (pCR) (2–4).  
OAC is an examplar model of an obesity- 
associated cancer, and obesity may underlie the 
marked increase in the incidence of OAC (1,5–7). 
Although the epidemiologic association between 
obesity and adenocarcinoma is well described, the 
impact of obesity on tumour biology, response to 
therapy, and outcomes, is unclear. Several studies 








risk of cancer recurrence and death, (8-10), while 
others have reported no difference in survival 
between obese and non-obese patients (11-14). 
Importantly, obesity status may play differential roles 
in tumour development during treatment and 
following surgery.  
The relationship between visceral adipose tissue 
(VAT) and radioresponse has not been investigated. 
The radioresistant phenotype is correlated with 
features such as altered DNA repair (15), cell cycle 
checkpoint operation (15), telomere biology (16), reac-
tive oxygen species (ROS) biology (17), and induction 
of apoptosis (15), all of which are hypothesized to be 
affected by visceral adiposity. Obesity is associated 
with a state of low-grade chronic inflammation that 
causes systemic oxidative stress (18,19), a mechanism 
by which ionizing radiation can damage cells (17). 
Obesity is associated with alterations in DNA repair 
mechanisms (20), and radioresistance of OAC is 
associated with DNA damage repair efficiency (21). 
Other putative mechanisms linking obesity and 
aggressive tumour behaviour include adipokine 
production, the insulin-like growth factor axis and sex 
steroids (22). Alterations in tumour biology are 
mediated not by adipocytes, but predominantly by 
secreted factors from the adipose tissue stromal 
vascular fraction (23). We have shown that visceral 
adipose conditioned media (ACM) in OAC patients is 
a rich source of adiponectin, leptin and VEGF (24), 
and metabolomic profiling has demonstrated an 
altered profile in ACM from viscerally obese 
compared to non-obese OAC patients (25). This 
current study assesses the interaction between obesity 
and radioresponse in vitro and in vivo in OAC.  
Methods 
OAC tumour and adipose tissue biobank 
Histologically proven OAC patients undergoing 
surgical resection, and elective non-oncological 
gastrointestinal surgeries were recruited to the study 
with patient consent. Full ethical approval was 
granted by the Adelaide and Meath Hospital 
(incorporating the National Children’s Hospital) 
(AMNCH) research ethics committee. Body weight, 
height, visceral fat area (VFA) and central waist 
circumference (WC) were measured. Body mass index 
(BMI) was calculated as weight (kg)/ height2 (m2). 
WC was measured to the nearest 0.1 cm using a tape 
measure midway between the uppermost border of 
the iliac crest and the lower border of the costal 
margin in the midaxillary line after respiratory 
exhalation while the patient was in a standing 
position (26). VFA was calculated from a 
pre-operative diagnostic computed tomography (CT) 
scan by an experienced radiologist, using a validated 
technique (27,28). A VFA in excess of 163.8 cm2 (men) 
and 80.1 cm2 (women) was classified as obese, or WC 
in excess of 94cm (men) and 80cm (women) was used 
where VFA wasn’t available (26). Standard operating 
procedures for the collection, storage and analysis of 
specimens were used (29). 
Visceral adipose tissue processing and cell 
co-culture with visceral ACM 
Omental adipose tissues were excised at the 
beginning of the surgical resections; adipose tissue 
was minced, washed with sterile PBS, and cultured in 
M199 media (Gibco) (5 g adipose tissue in 10mL 
media) for 72 hours. The adipose tissue culture was 
filtered to remove adipose tissue fragments and the 
supernatant (ACM) stored at -80°C. The OE33P and 
OE33R isogenic model of radioresistance were 
cultured as previously described (21) and treated with 
M199 control media or ACM at 37°C in 95% 
humidified air and 5% CO2 for 24 hours.  
Clonogenic assay to assess radiosensitivity 
OE33P and OE33R cells were co-cultured for 24 
hours with M199 control media or ACM, cells were 
irradiated with 0 or 2 Gy X-ray radiation using a 
Gulmay Medical X-ray generator, (RS225) (Gulmay 
Medical), at a dose rate of 3.25 Gray (Gy) per minute. 
Cells were cultured for 7–14 days to allow surviving 
colonies to reach maximum density without merging 
of colonies. Cells were stained with crystal violet dye 
for 30 minutes, dye removed and colonies consisting 
of 50 cells or more counted. Plating efficiencies (PE), 
which are the fraction of colonies from untreated cells, 
were calculated using the formula: PE= No. colonies/ 
No. cells seeded. The surviving fraction (SF), which is 
the number of colonies produced after treatment, 
expressed in terms of PE, was calculated using the 
formula: SF= No. colonies/(No. cells seeded × PE).  
Metabolomic profiling 
A volume of 250 µL deuterium and 10 µL 
sodium trimethyl [2,2,3,3-2H4] propionate (TSP) (0.005 
g/mL) were added to each 300 µL ACM sample. 
Spectra were acquired on a 600-MHz Varian nuclear 
magnetic resonance (NMR) spectrometer (Varian 
Limited, Oxford, United Kingdom) by using the first 
increment of a NOESY (Nuclear overhauser effect 
spectroscopy) pulse (sequence at 251C). 1H NMR 
ACM spectra were processed with Chenomx software 
(version 6; Chenomx Edmonton, Canada) and were 
phase and baseline corrected. Spectra were integrated 
into bins consisting of spectral regions of 0.001 ppm. 
The water region was excluded, and data normalized 
to the total area of the spectral integral. Discrimina-
ting metabolites were identified by using libraries of 




pure metabolites developed in-house and the Chen-
omx database library. Acquisition of samples resulted 
in spectra containing a number of peaks, representing 
proton resonance in 1H NMR.  
Adipokine receptor gene expression following 
co-culture with ACM 
Following co-culture of OE33P and OE33R cells 
with ACM, RNA was isolated using TriReagent and 
reverse transcribed as previously described (25). 
Adipokine gene expression (Adiponectin Receptor 1, 
Adiponectin Receptor 2, Leptin Receptor, Neuropilin- 
1), was measured by qPCR using a TaqMan® assay kit 
(Applied Biosystems), and 18S was used as an 
endogenous control for data normalisation. Analysis 
was performed using SDS 2.3 and SDS RQ 1.2 relative 
quantification software (Applied Biosystems). One 
sample was set as the calibrator for analysis. Gene 
expression was expressed as fold difference in 
expression relative to control. 
Retrospective analysis of patient associations 
between obesity and radiation sensitivity  
A retrospective analysis of patients with 
resectable oesophageal or oesophagogastric junction 
adenocarcinoma treated with NA CRT (neoadjuvant 
chemoradiotherapy) at St. James’s Hospital was 
performed. Clinical, pathological and survival data 
were retrieved from our cancer database. All resected 
tumours were staged in accordance with the Ameri-
can Joint Committee on Cancer (AJCC) (30). The 
extent of residual carcinoma in the surgical specimen 
was assigned a tumour regression grade (31). Tumour 
regression grade (TRG) 1-3 was considered to 
represent a good response to therapy, TRG 4-5 a poor 
response to therapy. Response to therapy was also 
classified accordinng to the modified Mandard 
three-point TRG that distinguishes complete, partial, 
and minimal or non-responders (32). 
Statistical Analysis 
Statistical analysis was performed using 
Graphpad Prism 5 software and SPSS version 18 for 
Windows software. Unless otherwise stated, data 
were expressed as mean ± standard error of the mean 
(SEM). Clinical data was expressed as the median. 
Unpaired t-tests and the Mann-Whitney U test were 
used to examine statistical significance between 
unpaired groups of parametric and non-parametric 
data respectively. Categorical variables were analysed 
by Chi-square and Fisher’s exact tests. One-way 
analysis of variance (ANOVA) and Tukey multiple 
comparisons post-hoc test were performed where the 
number of groups was three or more. RR refers to 
relative risk, 95% CI to 95% confidence interval. 
Survival analysis was performed using Kaplan-Meier 
curves and log-rank test and calculated from date of 
diagnosis to the first event (recurrence, progression, 
death or end of the follow-up period).  
For metabolomic data analyses, multivariate 
metabolite data analyses were performed with Simca- 
P+ software (version 11.0; Umetrics, Umea°, Sweden). 
The 1H NMR spectra were analysed using two pattern 
recognition methods; principal component analysis 
(PCA) (unsupervised) sets to explore any overall 
trends in the data; and partial least square discrimin-
ant analysis (PLS-DA). The variable importance in the 
projection (VIP) value of each variable in the model 
was calculated to indicate its contribution to the 
classification of samples. Variables with a VIP value 
>1.5 were considered important in discriminating 
between groups. The quality of all models was judged 
by the goodness-of-fit parameter (R2) and the predic-
tive ability parameter (Q2), which is calculated by an 
internal cross-validation of the data and the predicta-
bility calculated on a leave-out basis. For all analysis, 
p ≤0.05 was considered to be statistically significant.  
Results 
Visceral ACM increases sensitivity to radiation 
in OE33P and OE33R cells 
Clonogenic assay was used to assess sensitivity 
to 2 Gy X-ray radiation in OE33P and OE33R cells 
following incubation with M199 control media or 
ACM from non-cancer patients (non-cancer cohort, 
n=5) (Figure 1A, B), ACM from OAC patients who 
had not undergone NA CRT prior to surgery (surgery 
only OAC cohort, n=14) (Figure 1C, D), and ACM 
from OAC patients who received NA CRT therapy 
prior to surgery (NA CRT OAC cohort, n=10) (Figure 
1E, F). Anthropometric data for patient ACM used in 
clonogenic assay is summarised in supplementary 
table 1. OE33P cells incubated with ACM from the 
non-cancer and surgery only OAC cohort did not 
demonstrate any significant change in sensitivity to 2 
Gy X-ray radiation, when compared to cells incubated 
with M199 control media (Figure 1A and C). OE33P 
cells treated with ACM from the NA CRT OAC cohort 
demonstrated a statistically significant increase in 
radiosensitivity to 2 Gy, when compared to cells 
treated with M199 control media (p=0.009, Figure 1E). 
Interestingly, OE33R cells were significantly more 
radiosensitive following co-culture with ACM from 
all three patient groups, the non-cancer cohort 
(p=0.03, Figure 1B), the surgery only OAC cohort 
(p=0.002, Figure 1D) and the NA CRT OAC cohort 
(p<0.0001, Figure 1F), compared to cells treated with 
M199 control media. Radiosensitivity was significant-
ly increased in OE33R cells treated with ACM from 




NA CRT OAC patients compared to cells treated with 
ACM from the radiation naïve OAC patient cohort 
(p=0.003, Figure 1G). The ACM used in this study was 
generated from obese and non-obese OAC patients, 
but no differences in survival fractions of OE33P and 
OE33R cells were observed when ACM from 
non-obese compared to obese patients was analysed 
(data not shown), indicating that it is the visceral 
adipose tissue itself which can increase radiosensitiv-
ity, particularly in cells that are radioresistant.  
Metabolomic profiling of ACM from three 
patient cohorts  
To investigate if the metabolites secreted in ACM 
differ between the three patient cohorts, we perform-
ed metabolomic profiling of ACM using nuclear mag-
netic resonance spectroscopy (NMR). Anthropometric 
data for patient ACM used in metabolomic screening 
is summarised in supplementary table 2. A represent-
tative PCA plot showing separation on the basis of the 
three patient cohorts (non-cancer, surgery only OAC, 
and NA CRT OAC patients) is depicted in Figure 2A 
(R2=0.736). A robust PLS-DA model (Figure 2B) was 
built to further explore the differences (R2=0.453, Q2= 
0.235). To aid comparison and identification or 
regions of difference a pairwise comparison was perf-
ormed. The most influential peaks in the models were 
identified and a metabolite assigned to each peak. 
Semi-quantitative concentrations were compared 
between groups for the most influential metabolites. 
A PCA plot of 1H NMR ACM data for non- 
cancer patients versus surgery only OAC patients 
showed separation of the two cohorts, (R2=0.699, 
Figure 2C). A PLS-DA model was built to compare 
ACM profiles from the two cohorts (R2=0.479, Q2= 
0.304, Figure 2D). Glucose was significantly increased 
(p=0.019), whilst threonine (p=0.014) lysine, (p=0.017), 
and valine (p=0.029) were all significantly decreased 
in ACM from non-cancer patients, when compared to 
surgery only OAC patients (Table 1A).  
PCA and PLS-DA plots revealed separation 
between ACM from non-cancer and NA CRT OAC 
patients (Figure 2E, R2=0.0474, Q2=0.318). ACM from 
non-cancer patients demonstrated significantly 
increased glucose (p=0.012) but significantly 
decreased threonine (p=0.005) lysine, (p=0.004), valine 
(p=0.007), isoleucine (p=0.039) and glycine (p=0.05) 
when compared to NA CRT OAC patients (Table 1B). 
Adipokine receptor expression differs between 
OE33P and OE33R at baseline and following 
culture in visceral ACM 
Gene expression of four adipokine receptors 
representing abundant adipokines in non-obese and 
obese VAT was assessed in OE33P and OE33R cell 
lines both at baseline and following co-culture with 
ACM; adiponectin receptor 1 (AR1); adiponectin 
receptor 2 (AR2); leptin receptor (LepR); and the 
VEGF receptor neuropilin-1 (NRP1). Anthropometric 
data for patient ACM used in these analyses is shown 
in supplementary table 3.  
  
 
Figure 1. ACM increases radiosensitivity in OE33P and OE33R. OAC 
cells were treated with either M199 control media or ACM from non-cancer 
patients (n=5), ACM from surgery only OAC patients (OAC patients who had 
not undergone NA CRT) (n=14), or ACM from OAC patients who had 
previously undergone NA CRT (n=10) for 24hrs, and sensitivity to 2 Gy X-ray 
radiation was assessed. (A) Co-culture of OE33P cells with ACM from 
non-cancer patients did not significantly alter radiosensitivity. (B) Co-culture of 
OE33R cells with ACM from non-cancer patients significantly increased 
radiosensitivity, when compared to M199 control media (p=0.03). (C) OE33P 
cells treated with ACM from surgery only OAC patients did not demonstrate 
significantly altered radiosensitivity. (D) OE33R cells treated with ACM from 
surgery only OAC patients demonstrated significantly increased sensitivity to 2 
Gy, when compared to M199 control media (p=0.002). (E) OE33P cells treated 
with ACM from NA CRT OAC patients demonstrated significantly increased 
sensitivity to 2 Gy, when compared to M199 control media (p=0.009). (F) 
OE33R cells treated with ACM from NA CRT OAC patients demonstrated 
significantly increased sensitivity to 2 Gy (p<0.0001), when compared to M199 
control media. (G) OE33R cells treated with ACM from NA CRT OAC 
patients showed significantly increased sensitivity to 2 Gy, when compared to 
cells treated with ACM from surgery only OAC patients (p=0.003). Data are 
expressed as mean ± SEM. Statistical analysis was performed using unpaired 
student’s t test. Statistical analysis was performed using one-way ANOVA with 
Tukey post-hoc correction. *p<0.05, **p<0.001, ***p<0.0001 




Table 1A. Metabolites discriminating non-cancer patients versus 
surgery only OAC patients, and non-cancer patients versus NA 
CRT OAC patients. A. VIPs generated from the PLS-DA of 
non-cancer patients versus surgery only OAC patients 
    Non-cancer   Surgery only 
OAC 
    
ppm VIP [1] Mean SD  Mean SD Metabolite P-value 
1.305 6.58509 0.0128 0.0106  0.0304 0.008 Threonine 0.014 
1.865 2.22582 0.0019 0.0014  0.0039 0.0008 Lysine 0.017 
3.845 2.02298 0.0022 0.0012  0.0005 0.0002 Glucose 0.019 
1.035 1.95987 0.0011 0.001  0.0027 0.0011 Valine 0.029 
3.515 3.03494 0.0008 0.0003  0.0019 0.0013 Glycerol NS 
1.315 7.33073 0.0492 0.0402  0.0827 0.0277 Lactate  NS 
1.325 5.31929 0.0582 0.0484  0.0834 0.0284 Lactate NS 
Glucose was significantly increased (p=0.019), whilst threonine (p=0.014) lysine, 
(p=0.017), and valine (p=0.029) were all significantly decreased in ACM from 
non-cancer patients, when compared to surgery only OAC patients. 
VIP scores are indicated. For each metabolite, only peak is presented here. VIP= 
Variable in the Projection; PLS-DA= Partial least square discriminant analysis; 
PPM=Parts per million; NS=Non-significant 
 
Table 1B. VIPs generated from the PLS-DA of non-cancer 
patients versus NA CRT OAC patients 
    Non-cancer  NA CRT OAC      
ppm VIP [2] Mean SD  Mean SD Metabolite P-value 
1.295 5.67466 0.0005 0.0061  0.0114 0.0042 Threonine 0.005 
1.885 2.18606 0.0013 0.0005  0.0029 0.001 Lysine 0.004 
3.745 2.09995 0.0025 0.001  0.0011 0.0002 Glucose 0.012 
1.035 2.26945 0.0011 0.001  0.0029 0.0008 Valine 0.007 
3.535 5.24455 0.0083 0.0076  0.0205 0.0111 Glycine 0.05 
1.225 2.15509 0.0011 0.0017  0.003 0.0011 Isoleucine 0.039 
1.445 3.68593 0.0085 0.0072  0.0023 0.0006 Alanine NS 
ACM from non-cancer patients demonstrated significantly increased glucose 
(p=0.012) but significantly decreased threonine (p=0.005) lysine, (p=0.004), valine 
(p=0.007), isoleucine (p=0.039) and glycine (p=0.05) when compared to NA CRT 
OAC patients. P-values are based on unpaired t-test. 
VIP scores are indicated. For each metabolite, only peak is presented here. VIP= 
Variable in the Projection; PLS-DA= Partial least square discriminant analysis; NA 




Expression of AR1 was significantly higher in 
OE33P cells compared to OE33R cells at baseline 
(p=0.008) (Figure 3A). There was a two-fold 
downregulation in AR1 expression in OE33P cells 
following 24 hours of ACM treatment compared to 
cells treated with control media (p=0.019). ACM 
treatment did not significantly alter AR1 expression in 
OE33R cells (Figure 3B). Expression of AR2 was 
significantly higher in OE33P cells compared to 
OE33R cells at baseline (p=0.015) (Figure 3C). AR2 
expression following ACM treatment was not altered 
in OE33P or OE33R (Figure 3D).  
Interestingly, levels of LepR were significantly 
lower in OE33P cells compared to OE33R cells at 
baseline (p=0.033) (Figure 3E). LepR expression was 
five-fold lower in OE33P compared to OE33R cells 
treated with ACM (p=0.0004), (Figure 3F). Levels of 
NRP1 were also significantly lower in OE33P cells 
compared to OE33R cells at baseline (p=0.038) (Figure 
3G). ACM induced a 13-fold upregulation in NRP1 
expression in OE33P cells (p=0.047), but did not alter 
NRP1 expression in OE33R cells (Figure 3H). 
Overweight and obese OAC patients 
demonstrate enhanced radiosensitivity 
compared to normal weight patients 
Between 1990 and 2012, 201 consecutive OAC 
patients completed neoadjuvant chemoradiotherapy 
(NA CRT) as part of their curative therapy, and had a 
surgical resection. Clinical and pathological data for 
this cohort is summarised in supplementary table 4.  
Overweight/obese patients were more likely to 
have a lower pathological T stage at surgery following 
NA CRT, when compared to normal weight patients, 
(Relative Risk (RR) 1.495, 95% Confidence Interval 
(CI) 1.094-1.938, p=0.02, Figure 4A), despite having 
similar clinical T stages prior to NA CRT. The number 
of lymph nodes analysed and lymph node positivity 
did not differ between normal and overweight/obese 
cohorts. Overweight/obese patients were more likely 
to achieve a good TRG response (TRG1-3) compared 
to normal weight patients (RR=2.141, 95% 
CI=1.374-3.336, p=0.002, Figure 4B). When patients 
with TRG 3 were excluded from the analysis, 
overweight/obese patients were still more likely to 
achieve a good (TRG 1-2) response following NA CRT 
(RR=3.259, 95% CI=1.269-8.368, p=0.004, Figure 4C). 
When classified according to the most recent TRG 
stratification(29), overweight/obese patients were still 
more likely to achieve a complete (TRG 1) or partial 
(TRG 2-3) response following NA CRT (p=0.0025), but 
the number of patients in each treatment response 
group was small (Supplementary figure 1). When 
classified into normal weight, overweight and obese 
categories, overweight patients were more likely to 
achieve a good (TRG 1-3) response following NA CRT 
compared to normal weight patients (RR=2.147, 95% 
CI=1.294-3.561, p=0.0041) (Supplementary figure 2A). 
Obese patients were more likely to achieve a good 
(TRG 1-3) response following NA CRT compared to 
normal weight patients (RR=2.130, 95% 
CI=1.157-3.923, p=0.01), (Supplementary figure 2B). 
There was no difference in TRG response in 
overweight compared to obese patients (data not 
shown). 
Direct logistic regression was performed to 
assess the impact of a number of factors on the 
likelihood of a good TRG response. The model 
contained six variables (age, gender, smoking history, 
ASA grade, clinical T stage, BMI classification). Only 
BMI classification independently predicted TRG 
response. Overweight and obese patients were three 
times more likely to achieve a good TRG response 
after controlling for all other factors in the model 
(OR=3.376, 95% CI=1.68-6.784, p=0.002). Obesity 




status was not associated with risk of recurrence and 
did not affect survival (Figure 4D). Five-year survival 
was 21%, with overall median disease-specific 
survival of 27 months (median survival for normal 
weight patients was 23 months, overweight/obese 
median survival was 30 months).  
Therefore, clinically we have shown that while 
there was no difference in preoperative clinical T 
stage between normal weight patients and 
overweight and obese patients, overweight and obese 
patients were more likely to have a lower pathological 
T stage at surgery and to achieve a good TRG 
response (TRG 1-3) to NA CRT. Obesity status did not 
influence rates of postoperative morbidity, recurrence 
or survival.  
Discussion 
Adenocarcinoma of the oesopahgus often 
presents late and confers a poor prognosis. Although 
response rates to chemotherapy and radiation therapy 
have improved, treatment resistance is a significant 
clinical challenge (1). Analysis of standard 
clinicopathological parameters does not predict 
response to NA CRT (30). This study demonstrates for 
the first time a role for obesity in modulating response 
to radiation. We show that radiosensitivity was 
increased in radioresistant OE33R cells treated with 
ACM, using ACM from three patient cohorts; 
non-cancer patients, radiation naïve OAC patients, 
and post NA CRT OAC patients. Therefore, increased 
radiosensitivity is not merely a bystander effect 
caused by previous exposure of the fat tissue to 
radiation, but a response induced by factors from the 
fat itself. However, radioresistance was lowest in cells 
treated with ACM from patients who had received 
NA CRT, suggesting that previous exposure to 
irradiation may have influenced the visceral fat in 
these patients, generating a more radioresponsive 
phenotype, mechanisms of which are unknown. As 
ACM from non-cancer patient and surgery only 
patients also decreased radioresistance in the 
radioresistant cells, this suggest that factors in the 
ACM driving this effect are not present as a 
consequence of malignancy, but may be 
driven by the inflammatory nature of the 
visceral fat tissue itself. Factors secreted 
into the tumour microenvironment such as 
cyclin D1, GDF-15, VEGF and MMP are 
known to modulate the radioresponse 
(34–37). Given the complexity of the 
cellular response to ionizing radiation, it is 
likely that multiple interacting processes 
can regulate sensitivity to radiation.  
Radioresistance was significantly 
lower in OE33R cells treated with ACM 
from NA CRT patients, compared to ACM 
from the radiation naïve OAC cohort, 
suggesting the ACM from these two 
cohorts may have distinct metabolic 
actions: previous radiation may have 
stimulated the visceral fat to release 
metabolites which could further alter the 
radioresponse. Metabolomic profiling did 
not demonstrate any difference in 
metabolites between surgery only ACM 
and NA CRT OAC patient ACM which 
might account for the difference in radio-
response seen in our isogenic model. 
However, ACM from surgery only and NA 
CRT OAC patients was significantly 
altered compared to non-cancer patients.  
Higher levels of threonine, lysine and 
valine, and lower levels of glucose were 
seen in the metabolome of both surgery 
only and NA CRT OAC patients compared 
to non-cancer patients. A serum metabolite 
 
 
Figure 2. The metabolic profile is altered in ACM from non-cancer patients 
compared to ACM from surgery only OAC patients and NA CRT OAC patients. (A) 
Principal component analysis (PCA) plot of NMR spectra from non-cancer patients (red triangles, 
n=6), surgery only OAC patients (black triangles, n=6) and NA CRT OAC patients (blue 
triangles, n=6), showed separation of the three patient cohorts (R2=0.736). (B) A partial 
least-squares discriminant analysis (PLS-DA) of 1H NMR data from was constructed. Separation 
of the three cohorts was seen, but the model was weak, (R2=0.453, Q2=0.235). Therefore, 
pairwise PCA and PLS-DA plots were constructed. (C) PCA plot of 1H NMR ACM data for two 
patient cohorts (non cancer cohort versus surgery only OAC cohort), (R2=0.699). (D) PLS-DA 
of 1H NMR ACM data for non-cancer cohort versus surgery only OAC cohort, (R2=0.479, 
Q2=0.304). (E) PCA plot of non cancer patients versus NA CRT OAC patients (R2=0.547). (F) 
PLS-DA of 1H NMR plasma data for non-cancer cohort versus NA CRT OAC cohort, (R2=0.474, 
Q2=0.318). A representative PCA and PLS-DA model showing separation of the surgery only 
OAC and NA CRT OAC cohorts was constructed, and separation of the two patient cohorts 
was seen, but the Q2 value indicated that the model was weak (data not shown). 




signature including elevated levels of threonine and 
isoleucine predicted response to chemotherapy in 
breast cancer patients (38). Metabolic profiling of 
OAC patients demonstrated increased serum levels of 
lysine and glucose in OAC patients, when compared 
to healthy controls (39). Previous metabolomic 
analysis of tumour tissue, serum and urine in 
oesophageal cancer demonstrated variation in the 
metabolites of glycolysis, lactic acid fermentation and 
amino acid synthesis in oesophago-gastric cancer (40). 
We have previously shown that altered energy 
metabolism is associated with radioresistance in OAC 
(41). Future analysis may allow identification of the 
metabolic pathways in adipose tissue associated with 
modulation of cancer risk in obese individuals. Mass 
spectrometry- based metabolomics has demonstrated 
utility for identifying biomarkers of ionizing radiation 
exposure in cellular, mouse and rat in vivo radiation 
models (42). In addition, metabolomic 
mapping of ovarian, endometrial, lung, renal 
and colorectal cancer have demonstrated 
alterations in serum or urine profiles (43). 
Systemic alterations in the metabolomic 
profile of urine and serum may influence the 
radioresponse in obese individuals; however 
they cannot explain the local effect of ACM 
on radioresponse in OAC cells, indicating 
that other mechanisms must play a greater 
role, possibly differential expression of 
adipokine receptors. 
Our study demonstrated that baseline 
adipokine receptor expression differs 
between OE33P and OE33R. AR1 and AR2 
expression was higher in OE33P compared 
to OE33R, while LepR and NRP1 expression 
was lower in OE33P compared to OE33R. 
Furthermore, following ACM treatment, 
expression of LepR was higher in OE33R 
compared to OE33P.  
Adiponectin is the most abundant 
adipokine (44), and over 90% of OACs 
express AR1 and AR2 (45). High expression 
of AR1 and AR2 is associated with prolong-
ed survival in lung, thyroid and gastric 
cancer (46–49). These findings are consistent 
with our in vitro data demonstrating that 
AR1 and AR2 levels are higher in radio-
responsive compared to radioresistant 
cancer. Adiponectin has been shown to 
inhibit tumour growth in animals (44), and 
recombinant adiponectin has anti-
proliferative and proapoptotic effects on 
oesophageal adenocarcinoma cell lines that 
express both AR1 and AR2 (50, 51), which 
may potentially contribute to delaying 
recovery from DNA damage following 
irradiation, enhancing radiosensitivity.  
Expression of LepR and NRP1 correl-
ates with aggressive tumour behaviour in 
OAC, and poor prognosis in a range of 
cancers (45,52–59), however, their associa-
tion with radiosensitivity status has not been 
investigated. We showed that LepR and 
NRP1 are upregulated in radioresistant 
 
Figure 3. Adipokine receptor expression is altered in radioresistant OAC cells. 
Expression of a panel of adipokine receptors was assessed in OE33P and OE33R cell lines at 
baseline and following treatment with ACM from OAC patients, using qPCR. (A) Expression of 
AR1 was significantly higher in OE33P compared to OE33R at baseline (p=0.008). (B) ACM 
induced a significant downregulation of AR1 expression in OE33P cells (p=0.019) but did not 
alter AR1 expression in OE33R. (C) Basal AR2 expression is significantly increased in OE33P 
cells, when compared to OE33R (p=0.015). (D) No significant difference in AR2 expression 
was demonstrated in OE33P or OE33R cells treated with ACM for 24 hours. (E) Basal LepR 
expression was significantly lower in OE33P, when compared to OE33R (p=0.033). (F) ACM 
treatment did not alter LepR expression in OE33P. LepR expression was significantly increased 
in OE33R cells following ACM treatment (p=0.006). LepR expression was significantly 
increased in OE33R compared to OE33P cells treated with ACM (p=0.0004) (G) NRP1 
expression was significantly lower in OE33P compared to OE33R (p=0.038). (H) ACM 
significantly upregulated NRP1 expression in OE33P cells (p=0.047), however NRP1 
expression in OE33R cells was not altered following ACM treatment. Data are expressed as 
mean ± SEM. Statistical analysis was performed using unpaired two-tailed student’s t-test to 
compare expression in OE33P versus OE33R and paired two-tailed student’s t-test to compare 
ACM treated cells versus control; *p<0.05, **p<0.001, ***p<0.0001. 




OAC. We and others have demonstrated that leptin 
promotes cell proliferation, angiogenesis and 
metalloproteinase expression in oesophageal and 
colonic cancer cell lines (45,60–63). The obese db/db 
mouse, which lacks a functional LepR, demonstrates 
increased susceptibility to radiation (64), and leptin 
upregulation is known to suppress therapy-induced 
apoptosis by inhibiting caspase activation (65).  
Our in vitro results demonstrating that ACM 
influences radiosensitivity were further supported by 
clinical data indicating an association between 
increased adiposity and improved radioresponse. 
Only 15-45% of patients undergoing NA CRT achieve 
a complete pathologic response and subsequently, 
have improved outcomes (66). It is not understood 
why tumours of identical pre-treatment stage, under-
going identical neo-adjuvant regimens, respond 
differently to NA CRT (66–70). Our study suggests 
that BMI status influences tumour regression in OAC. 
We have shown that patients who were overweight or 
obese were more likely to have a lower pathological T 
stage than normal weight patients, despite having 
similar clinical T stages prior to treatment, and were 
more likely to achieve a good tumour regression 
grade than normal weight patients. Our results were 
consistent across a number of TRG classification 
systems. Shridhar et al. specifically examined 
oncological and survival outcomes in a cohort of OAC 
patients who received NA CRT; BMI was not 
associated with tumour response (13). In our study, 
obesity status was not associated with recurrence or 
survival. Four studies investigating outcomes in OAC 
patients in relation to BMI have included a cohort of 
patients who received NA CRT, none of which 
demonstrated a difference in survival between obese 
and non-obese patients (11-14). Improved TRG 
outcome indicates improved locoregional control- 
however the effect on survival in obese patients may 
be offset by associated morbidities, salvage systemic 
therapies, early metastic events or treatment toxicity. 
A limitation of this retrospective study is the use of 
BMI obtained at the time of diagnosis, which might 
not reflect changes in BMI that occurred before 
diagnosis, and visceral fat area measurement of 
obesity might have more closely mirrored the obesity 
status (71–73) and should be the focus of future 
studies. 
Importantly, this study was strengthened by the 
focus on a homogeneous patient population of 
non-metastatic OAC patients that were all treated 
with NA CRT followed by resection, reducing the 
possibility of outcome differences due to stage or 
treatment differences. Our findings linking obesity 
and radiation response may translate into other 
cancer types and outcomes. 
 
 
Figure 4. Overweight/obese patients demonstrate enhanced response to NA CRT compared to normal weight OAC patients. (A) Normal weight 
patients were more likely to have higher pathological T stage (T stage 3-4) at resection, following NA CRT, when compared to overweight/obese patients (RR=1.456, 
95% CI=1.094-1.938, p=0.02). (B) Overweight/obese patients were twice as likely to achieve a good (TRG 1-3) response following NA CRT, when compared to 
normal weight patients (RR=2.141, 95% CI=1.374-3.336, p=0.002). (C) When patients with TRG 3 were excluded from the analysis, overweight/obese patients were 
three times as likely to achieve a good (TRG 1-2) response following NA CRT, when compared to normal weight patients (RR=3.259, 95% CI=1.269-8.368, p=0.004). 
(D) There was no statistically significant difference in survival in normal weight compared to overweight/obese patients. Median survival was 23 and 30 months 
respectively. Comparison of patient cohorts in terms of pathological T stage and TRG was performed using χ2 test. A p value of ≤0.05 was considered to be 
statistically significant. *p<0.05, **p<0.001; RR=relative risk; 95% CI=95% confidence interval. Survival was calculated from date of diagnosis to the first event (i.e. 
death or end of the follow-up period). Survival analysis was performed using Kaplan-Meier curves and log-rank test. 






This study suggests a link between obesity status 
and response to radiation. Further work is warranted 
to determine functionally the connection between 
these two processes. 
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